Bone Marrow Transplant News and Research RSS Feed - Bone Marrow Transplant News and Research

HICCC receives $18 million grant from the National Cancer Institute

HICCC receives $18 million grant from the National Cancer Institute

Outstanding basic research, a growing focus on translating discoveries into treatments, and a dedication to patient care have earned the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center Support Grant from the National Cancer Institute (NCI). [More]
Scientists grow fully functional organ in animal from transplanted laboratory-created cells

Scientists grow fully functional organ in animal from transplanted laboratory-created cells

Laboratory-grown replacement organs have moved a step closer with the completion of a new study. Scientists have grown a fully functional organ from transplanted laboratory-created cells in a living animal for the first time. [More]
UChicago Medicine and Advocate Health Care wins NIH grant to find new ways to prevent type 1 diabetes

UChicago Medicine and Advocate Health Care wins NIH grant to find new ways to prevent type 1 diabetes

The University of Chicago Medicine and Advocate Children's Hospital / Advocate Health Care have received a five-year, $1.8-million grant from the National Institutes of Health to find new ways to delay and prevent type 1 diabetes. The grant will establish the first Type 1 Diabetes TrialNet Clinical Center in Chicago. [More]
University of Chicago adds six new members to governing Board of Trustees

University of Chicago adds six new members to governing Board of Trustees

The University of Chicago Medical Center added six new members to its governing Board of Trustees, and named a new president of the medical staff. [More]
3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey). [More]
States of Maine and Rhode Island add SCID to newborn screening panels

States of Maine and Rhode Island add SCID to newborn screening panels

The Immune Deficiency Foundation commends the states of Maine and Rhode Island for adding Severe Combined Immune Deficiency to their states' newborn screening panels, effective August 1, 2014. These states join 21 other states currently screening newborns for SCID, ensuring over two thirds of all babies in the U.S. are now being screened. [More]
Blood-forming stem cell transplantation benefits infants with severe combined immunodeficiency

Blood-forming stem cell transplantation benefits infants with severe combined immunodeficiency

Babies who are born with severe combined immunodeficiency (SCID) can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering's Richard J. O'Reilly, MD, a world-renowned pioneer in the development of transplant protocols. [More]
Scientist develops highly accurate device for diagnosing fatal lung disease

Scientist develops highly accurate device for diagnosing fatal lung disease

A scientist from the University of Exeter has developed a simple, cheap and highly accurate device for diagnosing a frequently fatal lung disease which attacks immune deficient individuals such as cancer patients and bone marrow transplant recipients. [More]
Immune marker predicts infection risk in critically ill children with traumatic injuries

Immune marker predicts infection risk in critically ill children with traumatic injuries

Researchers studying critically ill children with traumatic injuries have identified an immune marker that predicts which patients are likely to develop a hospital-acquired infection. [More]
Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL). [More]
Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients. [More]
Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014. [More]
Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine. [More]
Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms. [More]
Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting. [More]
Melbourne researchers find link between necroptosis and inflammatory disease

Melbourne researchers find link between necroptosis and inflammatory disease

A team of Melbourne researchers has shown a recently discovered type of cell death called necroptosis could be the underlying cause of inflammatory disease. [More]
Comer Children's Hospital offers high-dose radiation therapy for relapsed neuroblastoma

Comer Children's Hospital offers high-dose radiation therapy for relapsed neuroblastoma

The University of Chicago Medicine Comer Children's Hospital has become the first in Illinois to offer pioneering, targeted, high-dose, intravenous radiation therapy for relapsed neuroblastoma and other difficult-to-treat cancers. [More]
Longer looks: Exercise to treat depression; crowdsourcing treatment decisions; nitroglycerin shortage

Longer looks: Exercise to treat depression; crowdsourcing treatment decisions; nitroglycerin shortage

Depression is the most common mental illness-;affecting a staggering 25 percent of Americans-;but a growing body of research suggests that one of its best cures is cheap and ubiquitous. [More]
Researchers suggest potential treatment target for HCMV infection

Researchers suggest potential treatment target for HCMV infection

Discovering where a common virus hides in the body has been a long-term quest for scientists. Up to 80 percent of adults harbor the human cytomegalovirus (HCMV), which can cause severe illness and death in people with weakened immune systems. [More]
CIBMTR recognizes SCCA's Fred Hutchinson Bone Marrow Transplant Program

CIBMTR recognizes SCCA's Fred Hutchinson Bone Marrow Transplant Program

The Fred Hutchinson Bone Marrow Transplant Program at Seattle Cancer Care Alliance was recently recognized by the Center for International Blood and Marrow Transplant Research for outperforming its expected one-year survival rate for allogeneic transplant patients. The results published by the CIBMTR, analyzed the National Marrow Donor Program's (NMDP) registry of 168 U.S. transplant centers over a three-year period for its 2013 Transplant Center-Specific Survival Report. [More]